论文部分内容阅读
IA-2-P2是由来自P277多肽的T表位与胰岛素瘤相关蛋白2(IA-2)的B表位组合而成的新疫苗肽,为验证其对1型糖尿病的治疗效果,采用多次小剂量注射链脲佐菌素(STZ)诱导C57BL/6雄性小鼠建立1型糖尿病模型,成模2 w后,sc 100μg多肽进行免疫治疗,间隔3 w免疫,共6次,每3 w收集被免疫动物的血清进行生化分析,测定血糖浓度和IgG抗体滴度并进行体重监测。结果显示IA-2-P2多肽能在一定程度上降低血糖,与对照组相比,IA-2-P2组终末平均血糖下降38%;并能维持小鼠的体重的稳定;多肽治疗能延长小鼠生存时间,在32 w观测期间,IA-2-P2组小鼠生存率达70%,较对照组40%的生存率有显著差异(P<0.05);并且具有免疫调节作用,ELISA结果显示多肽可以有效引起免疫应答产生,与对照组相比,抗体水平有显著差异(P<0.05)。
IA-2-P2 is a novel vaccine peptide consisting of the B epitope from the T epitope of P277 polypeptide and Insulin-associated protein 2 (IA-2). To validate its therapeutic effect on type 1 diabetes, A small dose of streptozotocin (STZ) induced C57BL / 6 male mice to establish type 1 diabetes model. After 2 weeks of modeling, immunized with 100 μg of sc 100 μg peptide, immunized 6 times every 3 w The sera of the immunized animals were collected for biochemical analysis, blood glucose concentration and IgG antibody titers were measured, and weight monitoring was performed. The results showed that IA-2-P2 polypeptide could lower blood glucose to a certain degree. Compared with the control group, the average terminal glucose concentration of IA-2-P2 group decreased by 38%; and the weight of mice maintained stable; Mice survival time, IA-2-P2 group survival rate of 70% during the 32 w observation period, compared with the control group 40% survival rate was significantly different (P <0.05); and immune regulation, ELISA results The results showed that the polypeptide could effectively induce the immune response. Compared with the control group, the antibody level was significantly different (P <0.05).